131 related articles for article (PubMed ID: 15843678)
21. [Treatment of dyslipidemia in the secondary prevention of coronary artery disease].
Syvänne M
Duodecim; 1998; 114(15):1503-8. PubMed ID: 11552239
[No Abstract] [Full Text] [Related]
22. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
Robson J
Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
[No Abstract] [Full Text] [Related]
23. Statins may not affect CD4 response.
Gadd C
IAPAC Mon; 2006 Feb; 12(2):33. PubMed ID: 17249133
[No Abstract] [Full Text] [Related]
24. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
Motz W
MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
[No Abstract] [Full Text] [Related]
25. Cardiovascular risk assessment and hyperlipidemia.
Becker J
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):277-85. PubMed ID: 18644510
[TBL] [Abstract][Full Text] [Related]
26. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
Gambhir DS; Gambhir JK; Sudha R
Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
[No Abstract] [Full Text] [Related]
27. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
[TBL] [Abstract][Full Text] [Related]
28. The use of lipid-lowering agents in HIV-infected patients.
Meienberg F; Battegay E; Bucher HC; Battegay M
J HIV Ther; 2001 May; 6(2):40-4. PubMed ID: 11501203
[No Abstract] [Full Text] [Related]
29. Drug treatment of lipid disorders.
Knopp RH
N Engl J Med; 1999 Aug; 341(7):498-511. PubMed ID: 10441607
[No Abstract] [Full Text] [Related]
30. Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
Haffner SM; Ashraf T
Manag Care Interface; 2000 Mar; 13(3):52-8. PubMed ID: 11066277
[TBL] [Abstract][Full Text] [Related]
31. The evaluation and management of dyslipidemia in HIV-infected patients.
Fichtenbaum CJ
AIDS Clin Care; 2001 Dec; 13(12):113-7, 120. PubMed ID: 11769116
[No Abstract] [Full Text] [Related]
32. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
33. The analysis by Manuel and colleagues creates controversy with headlines, not data.
Genest J; McPherson R; Frohlich J; Fodor G
CMAJ; 2005 Apr; 172(8):1033-4; discussion 1037. PubMed ID: 15824410
[No Abstract] [Full Text] [Related]
34. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
35. Optimal management of cholesterol levels and the prevention of coronary heart disease in women.
Mosca LJ
Am Fam Physician; 2002 Jan; 65(2):217-26. PubMed ID: 11820486
[TBL] [Abstract][Full Text] [Related]
36. Hyperlipidemia treatment in children: the younger, the better.
Gauer R
Am Fam Physician; 2010 Sep; 82(5):460. PubMed ID: 20822078
[No Abstract] [Full Text] [Related]
37. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
Calza L; Manfredi R; Chiodo F
J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
[TBL] [Abstract][Full Text] [Related]
38. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
[TBL] [Abstract][Full Text] [Related]
39. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
Am J Kidney Dis; 2003 Apr; 41(4 Suppl 3):I-IV, S1-91. PubMed ID: 12671933
[No Abstract] [Full Text] [Related]
40. Lipid abnormalities.
Dube M; Fenton M
Clin Infect Dis; 2003 Apr; 36(Suppl 2):S79-83. PubMed ID: 12652375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
